Released on April 27, 2020

Consolidated Financial Report
for the First Quater, 2020 (Unaudited)(Japan GAAP)
AnGes, Inc. https://www.anges.co.jp/

Listings: Mothers of the Tokyo Stock Exchange, Code 4563
Head Office: 7-7-15, Saito-Asagi, Ibaraki, Osaka, 567-0085, Japan

(Figures are rounded down to the nearest million yen)

1. Business Results for the First Quarter, 2020 (From Jan. 1, 2020 to Mar. 31, 2020)

(1) Results of Operations (Percentages indicate changes from the same period of the previous fiscal year)

	Revenues		Operating loss		Ordinary loss		Net loss	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%
1Q 2020	5	(92.4)	(974)	—	(922)	—	(919)	—
1Q 2019	75	2.4	(918)	—	(938)	—	(1,183)	—

**Comprehensive Income 1Q 2020 : (926) million yen 1Q 2019 : (932) million yen*

	Net loss per share	Diluted net loss per share
	Yen	Yen
1Q 2020	(8.56)	—
1Q 2019	(11.92)	—

(2) Financial Position

	Total assets	Total net assets	Shareholders' equity ratio
	Million yen	Million yen	%
Mar. 31, 2020	14,599	14,270	96.8
Dec. 31, 2019	12,524	12,055	95.5

**Shareholder's equity Mar. 31, 2020 : 14,128 million yen Dec. 31, 2019 : 11,962 million yen*

2. Dividend

	Dividend per share					Dividend (Total)
	1Q	2Q	3Q	4Q	Full-year	
	Yen	Yen	Yen	Yen	Yen	Million yen
FY 2019	—	0.00	—	0.00	0.00	—
FY 2020	—					
FY 2020 (Forecast)		0.00	—	0.00	0.00	—

3. Earnings Forecast for the Fiscal Year 2020 (From Jan. 1, 2020 to Dec. 31, 2020)
*The financial forecast for the fiscal year 2020 is not stated because the reasonable financial forecast cannot be calculated at this time.

Notes:

(1) Change of reporting entities (change of condition of significant consolidated subsidiaries) : None

(2) Accounting procedure peculiar to the quarterly consolidated financial statements : None

(3) Change of significant accounting and reporting policies for consolidated financial statements

1) Changes caused by revision of accounting standard : None
2) Changes in accounting policies other than 1) : None
3) Changes in accounting estimates : None
4) Restatement : None

(4) Number of shares issued and outstanding (common stock)

1) Number of shares issued and outstanding (including treasury shares)	Mar. 31, 2020	112,294,561 shares	Dec. 31, 2019	106,969,561 shares
2) Number of treasury shares	Mar. 31, 2020	91 shares	Dec. 31, 2019	91 shares
3) Average number of shares issued and outstanding	1Q 2020	107,499,745 shares	1Q 2019	99,330,422 shares

**Performance forecasts or any other future events containd in this report are based on currently available information which are believed to be reasonable at the time of forecasts. Actual results may differ from the forecasts due to various factors.*

***This financial report has been translated from Japanese original which has been prepared in accordance with generally accepted accounting principles in Japan, for reference purposes only. Also some changes are added to this report in order to present in a form more familiar to the readers outside Japan.*

AnGes, Inc
Consolidated Balance Sheets
(In thousands of yen)
(Unaudited)

	December 31, 2019	March 31, 2020
Assets		
Current assets		
Cash and deposits	10,040,595	9,317,970
Accounts receivable - trade	3,061	6,304
Finished goods	72,859	69,406
Raw materials and supplies	565,239	539,726
Advance payments - trade	173,310	165,515
Prepaid expenses	25,168	23,495
Consumption taxes receivable	106,349	141,669
Other	5,607	7,477
Total current assets	10,992,191	10,271,566
Non-current assets		
Property, plant and equipment		
Buildings	53,658	53,656
Accumulated depreciation	(9,055)	(10,028)
Buildings, net	44,603	43,628
Tools, furniture and fixtures	85,756	85,691
Accumulated depreciation	(80,918)	(81,025)
Tools, furniture and fixtures, net	4,838	4,665
Total property, plant and equipment	49,441	48,294
Investments and other assets		
Investment securities	1,418,644	4,149,363
Deferred tax assets	1,460	1,450
Leasehold and guarantee deposits	60,171	60,168
Other	2,690	69,146
Total investments and other assets	1,482,966	4,280,129
Total non-current assets	1,532,408	4,328,424
Total assets	12,524,600	14,599,990

AnGes, Inc
Consolidated Balance Sheets
(In thousands of yen)
(Unaudited)

	December 31, 2019	March 31, 2020
Liabilities		
Current liabilities		
Accounts payable - trade	183,014	124,081
Accounts payable - other	103,161	116,903
Accrued expenses	12,374	11,631
Income taxes payable	79,999	35,908
Deposits received	64,484	15,301
Total current liabilities	443,033	303,828
Non-current liabilities		
Deferred tax liabilities	2,302	2,089
Asset retirement obligations	23,913	23,920
Total non-current liabilities	26,215	26,010
Total liabilities	469,248	329,838
Net assets		
Shareholders' equity		
Share capital	13,291,912	14,838,360
Capital surplus	9,106,534	10,652,982
Retained earnings	(10,434,498)	(11,354,467)
Treasury shares	(30)	(30)
Total shareholders' equity	11,963,919	14,136,845
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	(5,413)	(10,679)
Foreign currency translation adjustment	3,925	2,658
Total accumulated other comprehensive income	(1,488)	(8,020)
Share acquisition rights	92,920	141,327
Total net assets	12,055,351	14,270,151
Total liabilities and net assets	12,524,600	14,599,990

AnGes, Inc
Consolidated Statements of Operations
(In thousands of yen)
(Unaudited)

	The First Quater (From Jan. 1 to Mar.31) 2019	2020
Business revenues		
Net sales of goods	73,058	-
Net sales of finished goods	-	5,731
Research and development revenues	2,500	-
Total business revenues	75,558	5,731
Business expenses		
Cost of sales	35,974	3,453
Research and development expenses	693,783	628,354
Selling, general and administrative expenses	264,180	348,075
Total business expenses	993,939	979,882
Operating loss	(918,380)	(974,150)
Non-operating income		
Interest income	550	551
Foreign exchange gains	-	71,089
Commission income	959	1,801
Gain on investments in investment partnerships	3,320	-
Total non-operating income	4,830	73,442
Non-operating expenses		
Share issuance cost	23,616	21,896
Subscription rights to shares issuance cost	-	106
Loss on investments in investment partnerships	-	179
Foreign exchange losses	1,321	-
Total non-operating expenses	24,937	22,182
Ordinary loss	(938,487)	(922,890)
Extraordinary income		
Gain on reversal of share acquisition rights	-	5,418
Total extraordinary income	-	5,418
Extraordinary losses		
Loss on valuation of investment securities	243,123	-
Total extraordinary losses	243,123	-
Loss before income taxes	(1,181,610)	(917,472)
Income taxes - current	2,231	2,453
Income taxes - deferred	43	43
Total income taxes	2,275	2,496
Loss	(1,183,886)	(919,969)
Loss attributable to owners of parent	(1,183,886)	(919,969)

AnGes, Inc
Consolidated Statements of Comprehensive Income
(In thousands of yen)
(Unaudited)

	The First Quater (From Jan. 1 to Mar.31) 2019	2020
Loss	(1,183,886)	(919,969)
Other comprehensive income		
Valuation difference on available-for-sale securities	250,939	(5,265)
Foreign currency translation adjustment	(10)	(1,266)
Total other comprehensive income	250,929	(6,532)
Comprehensive income	(932,956)	(926,501)
Comprehensive income attributable to		
owners of parent	(932,956)	(926,501)
non-controlling interests	-	-

Projects --- Current pipeline status

<Self-developed products>

Segment	Project	Target indications	Region	Development stage	Alliance partners
Medicine	HGF Plasmid (Beperminogene Perplasmid) *Collategene®*	Arteriosclerosis Obliterans with Lower Limb Ischemic Ulcers	Japan	Phase Ⅲ	Mitsubishi Tanabe Pharma Corporation (JP) *Marketing Rights*
	HGF Plasmid (Beperminogene Perplasmid)	Arteriosclerosis Obliterans with Lower Limb Ischemic Ulcers	US	Phase Ⅱb	Mitsubishi Tanabe Pharma Corporation (JP) *Marketing Rights*
	NF-κB Decoy Oligonucleotide	Chronic Disconegic Lumber Back Pain		Phase Ⅰb (US)	Available
	Hypertension DNA Vaccine	Hypertension		Phase Ⅰ/Ⅱa (AU)	Available
	Novel Coronavirus DNA Vaccine	Novel Coronavirus (COVID-19)	Japan	Pre-clinical	Available